TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.19), $0.02 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $10.38 million.

“Our organization made significant progress in the second quarter while navigating the COVID-19 pandemic and its impact on our business,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “We delivered a strong quarter of operational execution during very unique circumstances, quickly reducing our operating expenses, reorienting our sales force, and addressing our credit facility future minimum net revenue covenants. These strategic and operational changes and our reshaped Board of Directors and management team are focused on driving revenue and achieving our goal of reaching EBITDA break even in 2021, which we believe will result in long-term shareholder value.”

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.